TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07328451: A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

Sponsor: Denali Therapeutics Inc. · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 68 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,717,552

Rescue Site Savings

+$1,794,112

Unlock Full NCT07328451 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07328451 Rescue Dossier →